The Surprising Benefits of GLP-1s: More Than Just Weight Loss
In the world of healthcare, few drug classes have captured as much attention as GLP-1 receptor agonists. Initially known for their effectiveness in weight loss, these medications are now revealing a surprising array of benefits that extend far beyond the scales. As a physician and observer of this evolving landscape, I find myself captivated by the potential of GLP-1s to transform not just individual health, but also the way we think about and manage various conditions.
The Kidney Guardian
One of the most remarkable findings is the impact of GLP-1s on kidney health. In the FLOW trial, semaglutide demonstrated a 24% reduction in the risk of kidney failure and a slower decline in kidney function among adults with type 2 diabetes and chronic kidney disease. This is a significant breakthrough, as nephrology has long struggled with limited treatment options for diabetic kidney disease. The benefit appears to be independent of weight loss, suggesting a direct effect on kidney health.
Sleep Apnea Relief
Another surprising benefit is the potential of GLP-1s to treat sleep apnea. In the SURMOUNT-OSA trials, adults with obesity and moderate-to-severe obstructive sleep apnea who received tirzepatide experienced substantial improvements in sleep quality, reduced systemic inflammation, and lower blood pressure. This is a game-changer for those who struggle with CPAP adherence, as it offers a new, potentially more effective treatment option.
Fatty Liver Therapy
GLP-1s are also showing promise in the treatment of metabolic dysfunction-associated steatohepatitis (MASH), the leading cause of liver transplants. In the ESSENCE trial, semaglutide achieved resolution of steatohepatitis in 62.9% of patients without worsening fibrosis, compared to 34.3% on placebo. This is a significant advancement in a field that has long watched candidate drugs fail on the same endpoint.
Addiction Reduction
Perhaps one of the most unexpected benefits is the potential of GLP-1s to reduce the risk of addiction. In a study of 606,434 US veterans with type 2 diabetes, starting a GLP-1 receptor agonist was associated with a 14% lower risk of developing a substance use disorder, including reductions in alcohol, cannabis, cocaine, nicotine, and opioid use. This effect is thought to be mediated by GLP-1 receptors in brain regions that process reward.
Blood Clots and Cancer
GLP-1s are also showing promise in preventing blood clots in chronically inflamed patients. A retrospective study found a 31% lower risk of pulmonary embolism, a 17% lower risk of venous thromboembolism, and a 21% reduction in ER visits among GLP-1 users. This is particularly intriguing, as it suggests an anti-inflammatory effect that could be beneficial in a wide range of conditions.
In addition, there is a signal that GLP-1s may slow cancer progression. In an observational study of 12,112 patients with obesity-related cancers, GLP-1 users were 38-50% less likely to progress to stage IV disease. While this is an observational study and not a randomized trial, it suggests a potential for GLP-1s to play a role in cancer prevention and treatment.
Neurological Benefits
Finally, there is a growing body of evidence suggesting that GLP-1s may have neurological benefits. A Nature Medicine atlas mapped GLP-1 use against 175 health outcomes in nearly two million veterans with diabetes, finding reduced risks of substance use, psychotic disorders, seizures, neurocognitive disorders, coagulation disorders, cardiometabolic disease, and infectious illness. While this is an observational study, it suggests a potential for GLP-1s to play a role in neurological health.
The Macro-Medical Reframe
As we continue to uncover the surprising benefits of GLP-1s, it is clear that these medications are more than just weight loss drugs. They are metabolic and inflammatory drugs that happen to cause weight loss, with a long list of coincidental improvements. This shift in perspective has significant implications for insurers, payers, and patients. For insurers, it may mean reconsidering the cost-effectiveness of these drugs in light of their broader benefits. For patients, it may mean a new conversation about the potential risks and benefits of GLP-1s, including menstrual changes, restored fertility, muscle loss, and other less-discussed effects.
In my opinion, the future of GLP-1s is bright, but it is also complex. As we continue to explore their potential, we must also be mindful of the potential downsides and ensure that patients are fully informed and supported in their journey towards better health.
